AI in Drug R&D: At Last, the End of the Beginning

AI is becoming a dominant force in biopharma, with advocates and investors touting it as a transformative technology for drug R&D, while skeptics remain cautious. The discussion marks a shift from abstraction to practical application in the industry.

AI in Drug R&D: At Last, the End of the Beginning With the emergence of AI as an increasingly dominant force in industry and society , much of the early discussion around AI in biopharma has tended to treat it largely as an abstraction. Advocates and investors insist AI is a transformative superhuman technology poised to domesticate R&D, while cynics, including many grizzled drug hunters, tend to... Read More